| A network of heterogeneous hydrogen bonds in GNRA tetraloops FM Jucker, HA Heus, PF Yip, EHM Moors, A Pardi Journal of molecular biology 264 (5), 968-980, 1996 | 384 | 1996 |
| Towards cleaner production: barriers and strategies in the base metals producing industry EHM Moors, KF Mulder, PJ Vergragt Journal of cleaner production 13 (7), 657-668, 2005 | 190 | 2005 |
| Traditional and modern technology assessment: toward a toolkit J Van Den Ende, K Mulder, M Knot, E Moors, P Vergragt Technological Forecasting and Social Change 58 (1-2), 5-21, 1998 | 163 | 1998 |
| Demand articulation in emerging technologies: intermediary user organisations as co-producers? WPC Boon, EHM Moors, S Kuhlmann, REHM Smits Research Policy 40 (2), 242-252, 2011 | 119 | 2011 |
| Clinical comparability and European biosimilar regulations H Schellekens, E Moors Nature biotechnology 28 (1), 28-31, 2010 | 118 | 2010 |
| Science, technology and the ‘grand challenge’of ageing—Understanding the socio-material constitution of later life A Peine, A Faulkner, B Jæger, E Moors Technological Forecasting and Social Change 93, 1-9, 2015 | 111 | 2015 |
| Immunogenicity of mAbs in non-human primates during nonclinical safety assessment PJK van Meer, M Kooijman, V Brinks, CC Gispen-de Wied, B Silva-Lima, ... MAbs 5 (5), 810-816, 2013 | 92 | 2013 |
| Demand articulation in intermediary organisations: The case of orphan drugs in the Netherlands WPC Boon, EHM Moors, S Kuhlmann, REHM Smits Technological forecasting and social change 75 (5), 644-671, 2008 | 77 | 2008 |
| Exploring emerging technologies using metaphors–a study of orphan drugs and pharmacogenomics W Boon, E Moors Social science & medicine 66 (9), 1915-1927, 2008 | 70 | 2008 |
| Institutional power play in innovation systems: The case of Herceptin® P Kukk, EHM Moors, MP Hekkert Research Policy 45 (8), 1558-1569, 2016 | 64 | 2016 |
| Technology strategies for sustainable metals production systems: a case study of primary aluminium production in The Netherlands and Norway EHM Moors Journal of cleaner production 14 (12-13), 1121-1138, 2006 | 63 | 2006 |
| Caring for healthcare entrepreneurs—Towards successful entrepreneurial strategies for sustainable innovations in Dutch healthcare M Janssen, EHM Moors Technological Forecasting and Social Change 80 (7), 1360-1374, 2013 | 61 | 2013 |
| The dynamics of innovation: a multilevel co-evolutionary perspective EHM Moors, A Rip, JSC Wiskerke Koninklijke Van Gorcum, 2004 | 58 | 2004 |
| The ability of animal studies to detect serious post marketing adverse events is limited PJK van Meer, M Kooijman, CC Gispen-de Wied, EHM Moors, ... Regulatory Toxicology and Pharmacology 64 (3), 345-349, 2012 | 54 | 2012 |
| Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe WPC Boon, EHM Moors, A Meijer, H Schellekens Clinical Pharmacology & Therapeutics 88 (6), 848-853, 2010 | 54 | 2010 |
| Exploring dynamics and strategies of niche protection WPC Boon, EHM Moors, AJ Meijer Research Policy 43 (4), 792-803, 2014 | 49 | 2014 |
| User producer interaction in context R Nahuis, EHM Moors, REHM Smits Technological Forecasting and Social Change 79 (6), 1121-1134, 2012 | 49 | 2012 |
| Towards a sustainable system of drug development EHM Moors, AF Cohen, H Schellekens Drug discovery today 19 (11), 1711-1720, 2014 | 48 | 2014 |
| Conceptualizing patterns in the dynamics of emerging technologies: The case of biotechnology developments in the Netherlands T Van der Valk, EHM Moors, MTH Meeus Technovation 29 (4), 247-264, 2009 | 42 | 2009 |
| Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: a sociotechnical analysis R Achterbergh, P Lakeman, D Stemerding, EHM Moors, MC Cornel Health Policy 83 (2-3), 277-286, 2007 | 38 | 2007 |
